single_man
Print Page    E-mail Page    RSS    E-mail Alerts 

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary and cardiac diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

...
more >
Stock Quotemore >
C
$1.52
 Stock is Down 0.15 (8.98%)
Bellerophon (Nasdaq: BLPH)
Data as of 08/31/16 4:00 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
08/09/16
Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update
WARREN, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the second quarter ended June 30, 2016 and provided a business update. “This quarter, we made important progress on our development plans across our clinical pipeline,” stated Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics. “As planned, in June we enrolled our first patient in our Phase ... 
07/25/16
Bellerophon Receives Approval to Commence Phase 2 Trial in PH-COPD
-- Trial expected to commence in third quarter; Results to be reported by year end 2016 -- -- Previous data supporting testing long-term benefits of pulsed inhaled nitric oxide (iNO) reported in peer-reviewed International Journal of COPD -- WARREN, N.J., July 25, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced it has received health authority approval in Belgium to commence a Phase 2 trial for INOpulse, its pat... 
06/16/16
Bellerophon Therapeutics Announces Enrollment of the First Patient in the INOvation-1 Phase 3 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
WARREN, N.J., June 16, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, announced today that the first subject has been enrolled in the Phase 3 INOvation-1 clinical trial.  The first patient was enrolled by Jeremy Feldman, MD, Principal Investigator at Arizona Pulmonary Associates, Ltd. INOvation-1 is a clinical trial evaluating the efficacy and safety of the INOpulse® delivery system for the treatment of patients with Pulmonar... 
Upcoming Eventsmore >
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources